Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Biogen has decided to close down its digital ... the company and its interactions with health systems, with three locations in Boston, Zurich, and Paris employing around 150 team members.

That’s the conclusion of hiring managers at four of the state’s leading life sciences companies who spoke at a recent career ...

Canaccord Genuity has adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) by reducing the stock's price target to $8.00 from the previous $9.00, while maintaining a Hold rating on the shares. The ...

Stock Market Today saw a sharp decline as the Dow Jones plummeted 400 points following a rise in US Inflation to 3% YoY. The ...

In an editorial, J. Mocco, MD, of Mount Sinai Health System in New York City, characterized the DISTAL and ESCAPE-MeVO cohorts as being older and having higher baseline disability, which may have ...

The location is the company's headquarters for ... its employees as it explores strategic alternatives. Story Jan. 22 - Biogen: The neuro-focused biotech is making an undisclosed number of cuts ...

Mizuho Securities analyst Salim Syed maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $207.00.

Biogen (NASDAQ:BIIB) shares traded flat in the premarket on Wednesday after the Alzheimer’s drug developer reported better-than-expected Q4 2024 financials while its full-year outlook ...

Bernstein initiated coverage of Biogen (BIIB) with a Market Perform rating and $160 price target For the past five years, Biogen “has lived and died” on the outlook for Alzheimer’s ...